{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T17:32:27Z","timestamp":1772818347853,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2008,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>There is no standard palliative chemotherapy regimen in biliary tract cancers (BTC). Fluoropyrimidine or gemcitabine, with or without platinum, are most frequently used. We conducted this study to clarify the efficacy of palliative chemotherapy in BTC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Patients with unresectable BTC treated with palliative chemotherapy between Oct 2001 and Aug 2006 at Seoul National University Hospital were reviewed retrospectively. Histologically confirmed cases of intrahepatic cholangiocarcinoma, gallbladder cancer, extrahepatic bile duct cancer, and ampulla of Vater carcinoma were enrolled. We analyzed the efficacy of regimens: gemcitabine (G) <jats:italic>versus<\/jats:italic> fluoropyrimidine (F) and with or without platinum (P).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 243 patients were enrolled. 159 patients (65%) were male and the median age of the patients was 60 years (range 26\u201381). Intrahepatic cholangiocarcinoma, gallbladder cancer, extrahepatic bile duct cancer, and ampulla of Vater carcinoma were 92, 72, 58, and 21 cases, respectively. The median progression free survival (PFS) was 4.3 months (95% CI, 3.7\u20134.9) and median overall survival (OS) was 8.7 months (95% CI, 7.4\u201310.0). Ninety-nine patients received G-based chemotherapy (94 GP, 5 G alone), and 144 patients received F-based chemotherapy (83 FP, 61 F alone). The response rate (RR), disease control rate (DCR), PFS and OS of G-based chemotherapy <jats:italic>versus<\/jats:italic> F-based chemotherapy were 16.7% <jats:italic>vs<\/jats:italic>. 19.5% (P = 0.591), 52.8% <jats:italic>vs<\/jats:italic>. 58.9% (P = 0.372), 4.0 months <jats:italic>vs<\/jats:italic>. 4.3 months (P = 0.816), and 7.8 months <jats:italic>vs<\/jats:italic>. 9.1 months (P = 0.848), respectively. Sixty-six patients received F or G without P, and 177 patients received F or G with P. The RR, DCR, PFS and OS of chemotherapy without P <jats:italic>versus<\/jats:italic> chemotherapy including P were 12.7% <jats:italic>vs<\/jats:italic>. 20.6% (P = 0.169), 46.0% <jats:italic>vs<\/jats:italic>. 60.6% (P = 0.049), 3.3 months <jats:italic>vs<\/jats:italic>. 4.4 months (P = 0.887), and 10.6 months <jats:italic>vs<\/jats:italic>. 8.1 months (P = 0.257), respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>In unresectable BTC, F-based and G-based chemotherapy showed similar efficacy in terms of RR, DCR, PFS and OS. The benefit of adding P to F or G was not significant except for DCR. Further prospective studies which define the efficacy of various chemotherapeutic regimens in BTC are warranted.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2407-8-374","type":"journal-article","created":{"date-parts":[[2008,12,18]],"date-time":"2008-12-18T07:14:00Z","timestamp":1229584440000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Gemcitabine-based versusfluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study"],"prefix":"10.1186","volume":"8","author":[{"given":"Mi-Jung","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Do-Youn","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Se-Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Wan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seock-Ah","family":"Im","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae-You","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dae Seog","family":"Heo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yung-Jue","family":"Bang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,12,18]]},"reference":[{"key":"1312_CR1","first-page":"43","volume":"57","author":"A Jemal","year":"2007","unstructured":"Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA: a cancer journal for clinicians. 2007, 57: 43-66.","journal-title":"CA: a cancer journal for clinicians"},{"key":"1312_CR2","doi-asserted-by":"publisher","first-page":"103","DOI":"10.4143\/crt.2004.36.2.103","volume":"36","author":"HR Shin","year":"2004","unstructured":"Shin HR, Jung KW, Won YJ, Park JG: 2002 Annual Report of the Korea Central Cancer Registry: Based on Registered Data from 139 Hospitals. Cancer Res Treat. 2004, 36: 103-114.","journal-title":"Cancer Res Treat"},{"key":"1312_CR3","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1517\/14656566.6.2.211","volume":"6","author":"GD Leonard","year":"2005","unstructured":"Leonard GD, O'Reilly EM: Biliary tract cancers: current concepts and controversies. Expert opinion on pharmacotherapy. 2005, 6: 211-223. 10.1517\/14656566.6.2.211.","journal-title":"Expert opinion on pharmacotherapy"},{"key":"1312_CR4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1055\/s-2007-1007302","volume":"14","author":"JN Vauthey","year":"1994","unstructured":"Vauthey JN, Blumgart LH: Recent advances in the management of cholangiocarcinomas. Seminars in liver disease. 1994, 14: 109-114. 10.1055\/s-2007-1007302.","journal-title":"Seminars in liver disease"},{"key":"1312_CR5","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1093\/oxfordjournals.annonc.a010676","volume":"7","author":"B Glimelius","year":"1996","unstructured":"Glimelius B, Hoffman K, Sjoden PO, Jacobsson G, Sellstrom H, Enander LK, Linne T, Svensson C: Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol. 1996, 7: 593-600.","journal-title":"Ann Oncol"},{"key":"1312_CR6","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/1097-0142(19840915)54:6<965::AID-CNCR2820540603>3.0.CO;2-X","volume":"54","author":"G Falkson","year":"1984","unstructured":"Falkson G, MacIntyre JM, Moertel CG: Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer. 1984, 54: 965-969. 10.1002\/1097-0142(19840915)54:6<965::AID-CNCR2820540603>3.0.CO;2-X.","journal-title":"Cancer"},{"key":"1312_CR7","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1200\/JCO.1984.2.11.1245","volume":"2","author":"JH Harvey","year":"1984","unstructured":"Harvey JH, Smith FP, Schein PS: 5-Fluorouracil, mitomycin, and doxorubicin (FAM) in carcinoma of the biliary tract. J Clin Oncol. 1984, 2: 1245-1248.","journal-title":"J Clin Oncol"},{"key":"1312_CR8","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1023\/A:1008241008379","volume":"9","author":"M Ducreux","year":"1998","unstructured":"Ducreux M, Rougier P, Fandi A, Clavero-Fabri MC, Villing AL, Fassone F, Fandi L, Zarba J, Armand JP: Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol. 1998, 9: 653-656. 10.1023\/A:1008241008379.","journal-title":"Ann Oncol"},{"key":"1312_CR9","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.ejca.2004.10.026","volume":"41","author":"M Ducreux","year":"2005","unstructured":"Ducreux M, van Cutsem E, van Laethem JL, Gress TM, Jeziorski K, Rougier P, Wagener T, Anak O, Baron B, Nordlinger B: A randomised phase II trial of weekly high-dose 5-fluorouracil with and without folinic acid and cisplatin in patients with advanced biliary tract carcinoma: results of the 40955 EORTC trial. Eur J Cancer. 2005, 41: 398-403. 10.1016\/j.ejca.2004.10.026.","journal-title":"Eur J Cancer"},{"key":"1312_CR10","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00280-005-0095-3","volume":"57","author":"T Okusaka","year":"2006","unstructured":"Okusaka T, Ishii H, Funakoshi A, Yamao K, Ohkawa S, Saito S, Saito H, Tsuyuguchi T: Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer chemotherapy and pharmacology. 2006, 57: 647-653. 10.1007\/s00280-005-0095-3.","journal-title":"Cancer chemotherapy and pharmacology"},{"key":"1312_CR11","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1159\/000098109","volume":"70","author":"T Kiba","year":"2006","unstructured":"Kiba T, Nishimura T, Matsumoto S, Hatano E, Mori A, Yasumi S, Doi R, Ikai I, Kitano T, Nishimura T, Yoshikawa K, Ishiguro H, Yanagihara K, Doi E, Teramukai S, Fukushima M: Single-agent gemcitabine for biliary tract cancers. Study outcomes and systematic review of the literature. Oncology. 2006, 70: 358-365. 10.1159\/000098109.","journal-title":"Oncology"},{"key":"1312_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00280-007-0444-5","volume":"61","author":"J Lee","year":"2008","unstructured":"Lee J, Kim TY, Lee MA, Ahn MJ, Kim HK, Lim HY, Lee NS, Park BJ, Kim JS: Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. Cancer chemotherapy and pharmacology. 2008, 61: 47-52. 10.1007\/s00280-007-0444-5.","journal-title":"Cancer chemotherapy and pharmacology"},{"key":"1312_CR13","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1002\/cncr.21741","volume":"106","author":"ST Kim","year":"2006","unstructured":"Kim ST, Park JO, Lee J, Lee KT, Lee JK, Choi SH, Heo JS, Park YS, Kang WK, Park K: A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer. 2006, 106: 1339-1346. 10.1002\/cncr.21741.","journal-title":"Cancer"},{"key":"1312_CR14","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1093\/annonc\/mdi046","volume":"16","author":"S Thongprasert","year":"2005","unstructured":"Thongprasert S, Napapan S, Charoentum C, Moonprakan S: Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol. 2005, 16: 279-281. 10.1093\/annonc\/mdi046.","journal-title":"Ann Oncol"},{"key":"1312_CR15","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1093\/annonc\/mdh172","volume":"15","author":"JJ Knox","year":"2004","unstructured":"Knox JJ, Hedley D, Oza A, Siu LL, Pond GR, Moore MJ: Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience. Ann Oncol. 2004, 15: 770-774. 10.1093\/annonc\/mdh172.","journal-title":"Ann Oncol"},{"key":"1312_CR16","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1200\/JCO.2005.51.008","volume":"23","author":"JJ Knox","year":"2005","unstructured":"Knox JJ, Hedley D, Oza A, Feld R, Siu LL, Chen E, Nematollahi M, Pond GR, Zhang J, Moore MJ: Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol. 2005, 23: 2332-2338. 10.1200\/JCO.2005.51.008.","journal-title":"J Clin Oncol"},{"key":"1312_CR17","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1159\/000096249","volume":"70","author":"N Androulakis","year":"2006","unstructured":"Androulakis N, Aravantinos G, Syrigos K, Polyzos A, Ziras N, Tselepatiotis E, Samonis G, Kentepozidis N, Giassas S, Vamvakas L, Georgoulias V: Oxaliplatin as first-line treatment in inoperable biliary tract carcinoma: a multicenter phase II study. Oncology. 2006, 70: 280-284. 10.1159\/000096249.","journal-title":"Oncology"},{"key":"1312_CR18","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00280-006-0380-9","volume":"60","author":"YS Hong","year":"2007","unstructured":"Hong YS, Lee J, Lee SC, Hwang IG, Choi SH, Heo JS, Park JO, Park YS, Lim HY, Kang WK: Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer. Cancer chemotherapy and pharmacology. 2007, 60: 321-328. 10.1007\/s00280-006-0380-9.","journal-title":"Cancer chemotherapy and pharmacology"},{"key":"1312_CR19","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1093\/annonc\/mdm439","volume":"19","author":"YJ Kim","year":"2008","unstructured":"Kim YJ, Im SA, Kim HG, Oh SY, Lee KW, Choi IS, Oh DY, Lee SH, Kim JH, Kim DW, Kim TY, Kim SW, Heo DS, Yoon YB, Bang YJ: A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer. Ann Oncol. 2008, 19: 99-103. 10.1093\/annonc\/mdm439.","journal-title":"Ann Oncol"},{"key":"1312_CR20","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1038\/sj.bjc.6602208","volume":"91","author":"H Ueno","year":"2004","unstructured":"Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C: Phase II study of S-1 in patients with advanced biliary tract cancer. British journal of cancer. 2004, 91: 1769-1774. 10.1038\/sj.bjc.6602208.","journal-title":"British journal of cancer"},{"key":"1312_CR21","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/cncr.21621","volume":"106","author":"SH Park","year":"2006","unstructured":"Park SH, Park YH, Lee JN, Bang SM, Cho EK, Shin DB, Lee JH: Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma. Cancer. 2006, 106: 361-365. 10.1002\/cncr.21621.","journal-title":"Cancer"},{"key":"1312_CR22","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000, 92: 205-216. 10.1093\/jnci\/92.3.205.","journal-title":"J Natl Cancer Inst"},{"key":"1312_CR23","doi-asserted-by":"publisher","first-page":"407","DOI":"10.2307\/2530454","volume":"38","author":"JR Anderson","year":"1982","unstructured":"Anderson JR, Bernstein L, Pike MC: Approximate confidence intervals for probabilities of survival and quantiles in life-table analysis. Biometrics. 1982, 38: 407-416. 10.2307\/2530454.","journal-title":"Biometrics"},{"key":"1312_CR24","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1093\/jjco\/hyl075","volume":"36","author":"J Furuse","year":"2006","unstructured":"Furuse J, Okusaka T, Funakoshi A, Yamao K, Nagase M, Ishii H, Nakachi K, Ueno H, Ikeda M, Morizane C, Horikawa Y, Mizuno N: Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer. Japanese journal of clinical oncology. 2006, 36: 552-556. 10.1093\/jjco\/hyl075.","journal-title":"Japanese journal of clinical oncology"},{"key":"1312_CR25","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.critrevonc.2006.04.006","volume":"61","author":"LM Pasetto","year":"2007","unstructured":"Pasetto LM, D'Andrea MR, Falci C, Monfardini S: Gemcitabine in advanced biliary tract cancers. Critical reviews in oncology\/hematology. 2007, 61: 230-242. 10.1016\/j.critrevonc.2006.04.006.","journal-title":"Critical reviews in oncology\/hematology"},{"key":"1312_CR26","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1053\/sonc.2002.37380","volume":"29","author":"W Scheithauer","year":"2002","unstructured":"Scheithauer W: Review of gemcitabine in biliary tract carcinoma. Seminars in oncology. 2002, 29: 40-45.","journal-title":"Seminars in oncology"},{"key":"1312_CR27","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1023\/B:DRUG.0000011797.09549.53","volume":"22","author":"N Tsavaris","year":"2004","unstructured":"Tsavaris N, Kosmas C, Gouveris P, Gennatas K, Polyzos A, Mouratidou D, Tsipras H, Margaris H, Papastratis G, Tzima E, Papadoniou N, Karatzas G, Papalambros E: Weekly gemcitabine for the treatment of biliary tract and gallbladder cancer. Invest New Drugs. 2004, 22: 193-198. 10.1023\/B:DRUG.0000011797.09549.53.","journal-title":"Invest New Drugs"},{"issue":"Suppl 7","key":"1312_CR28","doi-asserted-by":"publisher","first-page":"vii73","DOI":"10.1093\/annonc\/mdl956","volume":"17","author":"F Giuliani","year":"2006","unstructured":"Giuliani F, Gebbia V, Maiello E, Borsellino N, Bajardi E, Colucci G: Gemcitabine and cisplatin for inoperable and\/or metastatic biliary tree carcinomas: a multicenter phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). Ann Oncol. 2006, 17 (Suppl 7): vii73-77. 10.1093\/annonc\/mdl956.","journal-title":"Ann Oncol"},{"key":"1312_CR29","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1159\/000134239","volume":"73","author":"L Manzione","year":"2007","unstructured":"Manzione L, Romano R, Germano D: Chemotherapy with gemcitabine and oxaliplatin in patients with advanced biliary tract cancer: a single-institution experience. Oncology. 2007, 73: 311-315. 10.1159\/000134239.","journal-title":"Oncology"},{"key":"1312_CR30","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1093\/jjco\/hym116","volume":"37","author":"N Yonemoto","year":"2007","unstructured":"Yonemoto N, Furuse J, Okusaka T, Yamao K, Funakoshi A, Ohkawa S, Boku N, Tanaka K, Nagase M, Saisho H, Sato T: A multi-center retrospective analysis of survival benefits of chemotherapy for unresectable biliary tract cancer. Japanese journal of clinical oncology. 2007, 37: 843-851. 10.1093\/jjco\/hym116.","journal-title":"Japanese journal of clinical oncology"},{"key":"1312_CR31","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1159\/000227396","volume":"51","author":"S Okada","year":"1994","unstructured":"Okada S, Ishii H, Nose H, Yoshimori M, Okusaka T, Aoki K, Iwasaki M, Furuse J, Yoshino M: A phase II study of cisplatin in patients with biliary tract carcinoma. Oncology. 1994, 51: 515-517.","journal-title":"Oncology"},{"key":"1312_CR32","first-page":"521","volume":"2","author":"AM Bergman","year":"1996","unstructured":"Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Peters GJ: Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res. 1996, 2: 521-530.","journal-title":"Clin Cancer Res"},{"key":"1312_CR33","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/BF00685830","volume":"32","author":"T Shirasaka","year":"1993","unstructured":"Shirasaka T, Shimamoto Y, Ohshimo H, Saito H, Fukushima M: Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo. Cancer chemotherapy and pharmacology. 1993, 32: 167-172. 10.1007\/BF00685830.","journal-title":"Cancer chemotherapy and pharmacology"},{"key":"1312_CR34","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1038\/sj.bjc.6603648","volume":"96","author":"F Eckel","year":"2007","unstructured":"Eckel F, Schmid RM: Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. British journal of cancer. 2007, 96: 896-902. 10.1038\/sj.bjc.6603648.","journal-title":"British journal of cancer"},{"key":"1312_CR35","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1200\/JCO.2005.05.3579","volume":"24","author":"PA Philip","year":"2006","unstructured":"Philip PA, Mahoney MR, Allmer C, Thomas J, Pitot HC, Kim G, Donehower RC, Fitch T, Picus J, Erlichman C: Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol. 2006, 24: 3069-3074. 10.1200\/JCO.2005.05.3579.","journal-title":"J Clin Oncol"},{"key":"1312_CR36","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1159\/000111117","volume":"72","author":"B Paule","year":"2007","unstructured":"Paule B, Herelle MO, Rage E, Ducreux M, Adam R, Guettier C, Bralet MP: Cetuximab plus gemcitabine-oxaliplatin (GEMOX) in patients with refractory advanced intrahepatic cholangiocarcinomas. Oncology. 2007, 72: 105-110. 10.1159\/000111117.","journal-title":"Oncology"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-8-374.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-8-374\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-8-374","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-8-374.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T02:26:31Z","timestamp":1630463191000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-8-374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["1312"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-8-374","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12]]},"assertion":[{"value":"30 August 2008","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2008","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2008","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"374"}}